About RIDGEBACK BIOTHERAPEUTICS LP
Ridgeback Biotherapeutics develops potential medications to treat infectious diseases with limited or no treatment options, such as Ebola and COVID-19. The company focuses on committing resources and expertise early in the pharmaceutical development cycle for poorly-understood diseases.
Developing medications for infectious diseasesAccelerating life-changing and life-saving solutions
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $19.3M | |
| Federal contract award | Department of Health and Human Services | $14.0M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to RIDGEBACK BIOTHERAPEUTICS LP right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.